DrugPatentWatch Database Preview
Drugs in Development Information for Omecamtiv Mecarbil
What is the drug development status for Omecamtiv Mecarbil?
Omecamtiv Mecarbil is an investigational drug.
There have been 8 clinical trials for Omecamtiv Mecarbil.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2018.
The most common disease conditions in clinical trials are Heart Failure, Ventricular Dysfunction, Left, and [disabled in preview]. The leading clinical trial sponsors are Amgen, Cytokinetics, and Servier.
There are fifteen US patents protecting this investigational drug and one hundred and ten international patents.
Summary for Omecamtiv Mecarbil
| US Patents | 15 |
| International Patents | 110 |
| US Patent Applications | 24 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2018-12-07) |
| Vendors | 55 |
Recent Clinical Trials for Omecamtiv Mecarbil
| Title | Sponsor | Phase |
|---|---|---|
| Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure | Cytokinetics | Phase 3 |
| Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure | Servier | Phase 3 |
| Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure | Amgen | Phase 3 |
Clinical Trial Summary for Omecamtiv Mecarbil
Top disease conditions for Omecamtiv Mecarbil
Top clinical trial sponsors for Omecamtiv Mecarbil
US Patents for Omecamtiv Mecarbil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Omecamtiv Mecarbil | Start Trial | Compounds, compositions and methods | Cytokinetics, Incorporated (South San Francisco, CA) | Start Trial |
| Omecamtiv Mecarbil | Start Trial | Compounds, compositions and methods | Cytokinetics, Inc. (South San Francisco, CA) | Start Trial |
| Omecamtiv Mecarbil | Start Trial | Compounds, compositions and methods | Cytokinetics, Inc. (South San Francisco, CA) | Start Trial |
| Omecamtiv Mecarbil | Start Trial | Disubstituted ureas and uses thereof in treating heart failure | Amgen, Inc. (Thousand Oaks, CA) | Start Trial |
| Omecamtiv Mecarbil | Start Trial | Ureas and their use in the treatment of heart failure | Cytokinetics, Inc. (South San Francisco, CA) | Start Trial |
| Omecamtiv Mecarbil | Start Trial | Certain Chemical entities, compositions and methods | Cytokinetics, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Omecamtiv Mecarbil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Omecamtiv Mecarbil | Argentina | 053405 | 2024-06-17 | Start Trial |
| Omecamtiv Mecarbil | Australia | 2005264988 | 2024-06-17 | Start Trial |
| Omecamtiv Mecarbil | Brazil | PI0512193 | 2024-06-17 | Start Trial |
| Omecamtiv Mecarbil | Canada | 2570999 | 2024-06-17 | Start Trial |
| Omecamtiv Mecarbil | China | 101035525 | 2024-06-17 | Start Trial |
| Omecamtiv Mecarbil | Cyprus | 1115716 | 2024-06-17 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
